% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Werner:277408,
      author       = {R. A. Werner and P. E. Hartrampf and W. P. Fendler$^*$ and
                      S. E. Serfling and T. Derlin and T. Higuchi and K. J. Pienta
                      and A. Gafita and T. A. Hope and M. G. Pomper and M. Eiber
                      and M. A. Gorin and S. P. Rowe},
      title        = {{P}rostate-specific {M}embrane {A}ntigen {R}eporting and
                      {D}ata {S}ystem {V}ersion 2.0.},
      journal      = {European urology},
      volume       = {84},
      number       = {5},
      issn         = {0302-2838},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2023-01362},
      pages        = {491-502},
      year         = {2023},
      note         = {2023 Nov;84(5):491-502},
      abstract     = {Prostate-specific Membrane Antigen Reporting and Data
                      System (PSMA-RADS) was introduced for standardized
                      reporting, and PSMA-RADS version 1.0 allows classification
                      of lesions based on their likelihood of representing a site
                      of prostate cancer on PSMA-targeted positron emission
                      tomography (PET). In recent years, this system has
                      extensively been investigated. Increasing evidence has
                      accumulated that the different categories reflect their
                      actual meanings, such as true positivity in PSMA-RADS 4 and
                      5 lesions. Interobserver agreement studies demonstrated high
                      concordance among a broad spectrum of 68Ga- or 18F-labeled,
                      PSMA-directed radiotracers, even for less experienced
                      readers. Moreover, this system has also been applied to
                      challenging clinical scenarios and to assist in clinical
                      decision-making, for example, to avoid overtreatment in
                      oligometastatic disease. Nonetheless, with an increasing use
                      of PSMA-RADS 1.0, this framework has shown not only
                      benefits, but also limitations, for example, for follow-up
                      assessment of locally treated lesions. Thus, we aimed to
                      update the PSMA-RADS framework to include a refined set of
                      categories in order to optimize lesion-level
                      characterization and best assist in clinical decision-making
                      (PSMA-RADS version 2.0).},
      keywords     = {Prostate carcinoma (Other) / Prostate-specific membrane
                      antigen (Other) / Reporting and data system (Other) /
                      Structured reporting (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37414701},
      doi          = {10.1016/j.eururo.2023.06.008},
      url          = {https://inrepo02.dkfz.de/record/277408},
}